Bexarotene 75mg capsules are a generic version of Valeant’s Targretin Capsules.
Mylan CEO Heather Bresch said: "Mylan’s launch of the first and only generic Targretin is another example of our commitment to expand access to high quality, more affordable medicines.
"The launch also strengthens Mylan’s growing oncology franchise of more than 30 approved oncology treatments, and associated supportive care and diagnostic products in the US.
"We look forward to continue meeting patient, payor and provider needs in this space."
According to IMS Health, Bexarotene 75mg Capsules had US sales of about $155.5m for the 12 months ending 31 March 2015.
Around 270 of Mylan ANDAs that represent $107.2bn in annual sales are still awaiting clearances from the FDA, with 47 of them being potential first-to-file opportunities, signifying $33.3bn in annual brand sales, for the year ending 31 December 2014.
The company offers a portfolio of more than 1,400 generic medications and it provides a range of antiretroviral therapies to around 50% of HIV/AIDS patients in developing countries.